Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,18059078,ch,The method had a very short chromatographic run time of 1.6 min.,Validation of a fully automated high throughput liquid chromatographic/tandem mass spectrometric method for roxithromycin quantification in human plasma. Application to a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18059078/),min,1.6,4419,DB00778,Roxithromycin
,17591264,Cmax,The values of Cmax were 10.16+/-1.46 and 10.34+/-1.66 microg x ml(-1) at 2.33+/-0.61 and 2.28+/-0.62 h respectively; of t1/2 were 9.00+/-1.58 and 8.68+/-1.66 h respectively; of AUC0-->Tn were 143.32 +/-25. 80 and 138.93+/-22.,[Relative bioavailability of roxithromycin dispersive tablets in healthy volunteers]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17591264/),[μg] / [ml],10.16,7633,DB00778,Roxithromycin
,17591264,Cmax,The values of Cmax were 10.16+/-1.46 and 10.34+/-1.66 microg x ml(-1) at 2.33+/-0.61 and 2.28+/-0.62 h respectively; of t1/2 were 9.00+/-1.58 and 8.68+/-1.66 h respectively; of AUC0-->Tn were 143.32 +/-25. 80 and 138.93+/-22.,[Relative bioavailability of roxithromycin dispersive tablets in healthy volunteers]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17591264/),[μg] / [ml],10.34,7634,DB00778,Roxithromycin
,17591264,t1/2,The values of Cmax were 10.16+/-1.46 and 10.34+/-1.66 microg x ml(-1) at 2.33+/-0.61 and 2.28+/-0.62 h respectively; of t1/2 were 9.00+/-1.58 and 8.68+/-1.66 h respectively; of AUC0-->Tn were 143.32 +/-25. 80 and 138.93+/-22.,[Relative bioavailability of roxithromycin dispersive tablets in healthy volunteers]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17591264/),h,9.00,7635,DB00778,Roxithromycin
,17591264,t1/2,The values of Cmax were 10.16+/-1.46 and 10.34+/-1.66 microg x ml(-1) at 2.33+/-0.61 and 2.28+/-0.62 h respectively; of t1/2 were 9.00+/-1.58 and 8.68+/-1.66 h respectively; of AUC0-->Tn were 143.32 +/-25. 80 and 138.93+/-22.,[Relative bioavailability of roxithromycin dispersive tablets in healthy volunteers]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17591264/),h,8.68,7636,DB00778,Roxithromycin
,17591264,AUC0-->Tn,The values of Cmax were 10.16+/-1.46 and 10.34+/-1.66 microg x ml(-1) at 2.33+/-0.61 and 2.28+/-0.62 h respectively; of t1/2 were 9.00+/-1.58 and 8.68+/-1.66 h respectively; of AUC0-->Tn were 143.32 +/-25. 80 and 138.93+/-22.,[Relative bioavailability of roxithromycin dispersive tablets in healthy volunteers]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17591264/),,143.32,7637,DB00778,Roxithromycin
,17591264,AUC0-->Tn,The values of Cmax were 10.16+/-1.46 and 10.34+/-1.66 microg x ml(-1) at 2.33+/-0.61 and 2.28+/-0.62 h respectively; of t1/2 were 9.00+/-1.58 and 8.68+/-1.66 h respectively; of AUC0-->Tn were 143.32 +/-25. 80 and 138.93+/-22.,[Relative bioavailability of roxithromycin dispersive tablets in healthy volunteers]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17591264/),,138.93,7638,DB00778,Roxithromycin
,17591264,AUC0-->infinity,49 microg x h x ml(-1) respectively; of AUC0-->infinity were 158.63+/-26.86 and 153.77+/-24.75 microg x h x ml(-1) for test and reference drugs.,[Relative bioavailability of roxithromycin dispersive tablets in healthy volunteers]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17591264/),[h·μg] / [ml],158.63,7639,DB00778,Roxithromycin
,17591264,AUC0-->infinity,49 microg x h x ml(-1) respectively; of AUC0-->infinity were 158.63+/-26.86 and 153.77+/-24.75 microg x h x ml(-1) for test and reference drugs.,[Relative bioavailability of roxithromycin dispersive tablets in healthy volunteers]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17591264/),[h·μg] / [ml],153.77,7640,DB00778,Roxithromycin
,17591264,Relative bioavailability,Relative bioavailability of the tested roxithromycin was 103.63%+/-14.04%.,[Relative bioavailability of roxithromycin dispersive tablets in healthy volunteers]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17591264/),%,103.63,7641,DB00778,Roxithromycin
,1425718,peak serum levels,"Pharmacokinetics after a single dose of roxithromycin were characterized by high peak serum levels (9.1 +/- 2.1 mg/l) and a long elimination half-life (7.2 +/- 2.5 h), resulting in a large area under the curve (116.9 +/- 32.7 mg h/l).",Pharmacokinetics of roxithromycin and influence of H2-blockers and antacids on gastrointestinal absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425718/),[mg] / [l],9.1,9020,DB00778,Roxithromycin
,1425718,elimination half-life,"Pharmacokinetics after a single dose of roxithromycin were characterized by high peak serum levels (9.1 +/- 2.1 mg/l) and a long elimination half-life (7.2 +/- 2.5 h), resulting in a large area under the curve (116.9 +/- 32.7 mg h/l).",Pharmacokinetics of roxithromycin and influence of H2-blockers and antacids on gastrointestinal absorption. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425718/),h,7.2,9021,DB00778,Roxithromycin
,1425718,area under the curve,"Pharmacokinetics after a single dose of roxithromycin were characterized by high peak serum levels (9.1 +/- 2.1 mg/l) and a long elimination half-life (7.2 +/- 2.5 h), resulting in a large area under the curve (116.9 +/- 32.7 mg h/l).",Pharmacokinetics of roxithromycin and influence of H2-blockers and antacids on gastrointestinal absorption. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1425718/),[h·mg] / [l],116.9,9022,DB00778,Roxithromycin
,2376427,biological half-life (beta-phase),"The biological half-life (beta-phase) of roxithromycin in cyclosporin patients was 34.4 (+/- 12.25) h (mean +/- SD), in azathioprine patients 23.4 (+/- 8.18) h and in healthy volunteers 17.0 (+/- 3.8) h.",Pharmacokinetics of roxithromycin in kidney grafted patients under cyclosporin A or azathioprine immunosuppression and in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2376427/),h,34.4,16171,DB00778,Roxithromycin
,2376427,biological half-life (beta-phase),"The biological half-life (beta-phase) of roxithromycin in cyclosporin patients was 34.4 (+/- 12.25) h (mean +/- SD), in azathioprine patients 23.4 (+/- 8.18) h and in healthy volunteers 17.0 (+/- 3.8) h.",Pharmacokinetics of roxithromycin in kidney grafted patients under cyclosporin A or azathioprine immunosuppression and in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2376427/),h,23.4,16172,DB00778,Roxithromycin
,2376427,biological half-life (beta-phase),"The biological half-life (beta-phase) of roxithromycin in cyclosporin patients was 34.4 (+/- 12.25) h (mean +/- SD), in azathioprine patients 23.4 (+/- 8.18) h and in healthy volunteers 17.0 (+/- 3.8) h.",Pharmacokinetics of roxithromycin in kidney grafted patients under cyclosporin A or azathioprine immunosuppression and in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2376427/),h,17.0,16173,DB00778,Roxithromycin
,2376427,total elimination constant (k10),"The total elimination constant (k10) was 0.046 (+/- 0.014), 0.068 (+/- 0.019) and 0.084 (+/- 0.036) h, respectively.",Pharmacokinetics of roxithromycin in kidney grafted patients under cyclosporin A or azathioprine immunosuppression and in healthy volunteers. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2376427/),h,0.046,16174,DB00778,Roxithromycin
,2376427,total elimination constant (k10),"The total elimination constant (k10) was 0.046 (+/- 0.014), 0.068 (+/- 0.019) and 0.084 (+/- 0.036) h, respectively.",Pharmacokinetics of roxithromycin in kidney grafted patients under cyclosporin A or azathioprine immunosuppression and in healthy volunteers. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2376427/),h,0.068,16175,DB00778,Roxithromycin
,2376427,total elimination constant (k10),"The total elimination constant (k10) was 0.046 (+/- 0.014), 0.068 (+/- 0.019) and 0.084 (+/- 0.036) h, respectively.",Pharmacokinetics of roxithromycin in kidney grafted patients under cyclosporin A or azathioprine immunosuppression and in healthy volunteers. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2376427/),h,0.084,16176,DB00778,Roxithromycin
,2376427,total clearance,"The total clearance was 0.79 (+/- 0.21), 1.45 (+/- 0.66) and 1.84 (+/- 0.56) l/h, respectively.",Pharmacokinetics of roxithromycin in kidney grafted patients under cyclosporin A or azathioprine immunosuppression and in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2376427/),[l] / [h],0.79,16177,DB00778,Roxithromycin
,2376427,total clearance,"The total clearance was 0.79 (+/- 0.21), 1.45 (+/- 0.66) and 1.84 (+/- 0.56) l/h, respectively.",Pharmacokinetics of roxithromycin in kidney grafted patients under cyclosporin A or azathioprine immunosuppression and in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2376427/),[l] / [h],1.45,16178,DB00778,Roxithromycin
,2376427,total clearance,"The total clearance was 0.79 (+/- 0.21), 1.45 (+/- 0.66) and 1.84 (+/- 0.56) l/h, respectively.",Pharmacokinetics of roxithromycin in kidney grafted patients under cyclosporin A or azathioprine immunosuppression and in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2376427/),[l] / [h],1.84,16179,DB00778,Roxithromycin
,2376427,areas under the serum level curves,"The areas under the serum level curves were 407.6 (+/- 118.3), 251.0 (+/- 106.6) and 180.7 (+/- 73.2) mg.h/l, respectively.",Pharmacokinetics of roxithromycin in kidney grafted patients under cyclosporin A or azathioprine immunosuppression and in healthy volunteers. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2376427/),[h·mg] / [l],407.6,16180,DB00778,Roxithromycin
,2376427,areas under the serum level curves,"The areas under the serum level curves were 407.6 (+/- 118.3), 251.0 (+/- 106.6) and 180.7 (+/- 73.2) mg.h/l, respectively.",Pharmacokinetics of roxithromycin in kidney grafted patients under cyclosporin A or azathioprine immunosuppression and in healthy volunteers. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2376427/),[h·mg] / [l],251.0,16181,DB00778,Roxithromycin
,2376427,areas under the serum level curves,"The areas under the serum level curves were 407.6 (+/- 118.3), 251.0 (+/- 106.6) and 180.7 (+/- 73.2) mg.h/l, respectively.",Pharmacokinetics of roxithromycin in kidney grafted patients under cyclosporin A or azathioprine immunosuppression and in healthy volunteers. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2376427/),[h·mg] / [l],180.7,16182,DB00778,Roxithromycin
,20095494,AUC(0-72 h),"After an oral administration of roxithromycin capsule, the pharmacokinetic parameters of roxithromycin, such as AUC(0-72 h) (66 076 microg x L x h(-1) and 70 334 microg x L x h(-1) for test and reference capsule, respectively) and AUC(0-infinity) (68 153 microg x L x h(-1) and 72 362 microg x L x h(-1)) were significantly similar.",[Pharmacokinetics and relative bioavailability study of roxithromycin tablet in Chinese healthy volunteers by LC-MS/MS]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20095494/),[l·μg] / [h],66 076,20982,DB00778,Roxithromycin
,20095494,AUC(0-72 h),"After an oral administration of roxithromycin capsule, the pharmacokinetic parameters of roxithromycin, such as AUC(0-72 h) (66 076 microg x L x h(-1) and 70 334 microg x L x h(-1) for test and reference capsule, respectively) and AUC(0-infinity) (68 153 microg x L x h(-1) and 72 362 microg x L x h(-1)) were significantly similar.",[Pharmacokinetics and relative bioavailability study of roxithromycin tablet in Chinese healthy volunteers by LC-MS/MS]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20095494/),[l·μg] / [h],70 334,20983,DB00778,Roxithromycin
,20095494,AUC(0-infinity),"After an oral administration of roxithromycin capsule, the pharmacokinetic parameters of roxithromycin, such as AUC(0-72 h) (66 076 microg x L x h(-1) and 70 334 microg x L x h(-1) for test and reference capsule, respectively) and AUC(0-infinity) (68 153 microg x L x h(-1) and 72 362 microg x L x h(-1)) were significantly similar.",[Pharmacokinetics and relative bioavailability study of roxithromycin tablet in Chinese healthy volunteers by LC-MS/MS]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20095494/),[l·μg] / [h],68 153,20984,DB00778,Roxithromycin
,20095494,AUC(0-infinity),"After an oral administration of roxithromycin capsule, the pharmacokinetic parameters of roxithromycin, such as AUC(0-72 h) (66 076 microg x L x h(-1) and 70 334 microg x L x h(-1) for test and reference capsule, respectively) and AUC(0-infinity) (68 153 microg x L x h(-1) and 72 362 microg x L x h(-1)) were significantly similar.",[Pharmacokinetics and relative bioavailability study of roxithromycin tablet in Chinese healthy volunteers by LC-MS/MS]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20095494/),[l·μg] / [h],72 362,20985,DB00778,Roxithromycin
,20095494,C(max),"For test and reference capsule, the values of C(max) were 6 631.5 microg x L(-1) and 7 033.9 microg x L(-1) respectively, of T1/2 were 15.39 +/- 4.61 h and 16.06 +/- 5.56 h, and of T(max) were 1.3 +/- 0.9 h and 1.4 +/- 0.7 h respectively.",[Pharmacokinetics and relative bioavailability study of roxithromycin tablet in Chinese healthy volunteers by LC-MS/MS]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20095494/),[μg] / [l],6 631.5,20986,DB00778,Roxithromycin
,20095494,C(max),"For test and reference capsule, the values of C(max) were 6 631.5 microg x L(-1) and 7 033.9 microg x L(-1) respectively, of T1/2 were 15.39 +/- 4.61 h and 16.06 +/- 5.56 h, and of T(max) were 1.3 +/- 0.9 h and 1.4 +/- 0.7 h respectively.",[Pharmacokinetics and relative bioavailability study of roxithromycin tablet in Chinese healthy volunteers by LC-MS/MS]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20095494/),[μg] / [l],7 033.9,20987,DB00778,Roxithromycin
,20095494,T1/2,"For test and reference capsule, the values of C(max) were 6 631.5 microg x L(-1) and 7 033.9 microg x L(-1) respectively, of T1/2 were 15.39 +/- 4.61 h and 16.06 +/- 5.56 h, and of T(max) were 1.3 +/- 0.9 h and 1.4 +/- 0.7 h respectively.",[Pharmacokinetics and relative bioavailability study of roxithromycin tablet in Chinese healthy volunteers by LC-MS/MS]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20095494/),h,15.39,20988,DB00778,Roxithromycin
,20095494,T1/2,"For test and reference capsule, the values of C(max) were 6 631.5 microg x L(-1) and 7 033.9 microg x L(-1) respectively, of T1/2 were 15.39 +/- 4.61 h and 16.06 +/- 5.56 h, and of T(max) were 1.3 +/- 0.9 h and 1.4 +/- 0.7 h respectively.",[Pharmacokinetics and relative bioavailability study of roxithromycin tablet in Chinese healthy volunteers by LC-MS/MS]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20095494/),h,16.06,20989,DB00778,Roxithromycin
,20095494,T(max),"For test and reference capsule, the values of C(max) were 6 631.5 microg x L(-1) and 7 033.9 microg x L(-1) respectively, of T1/2 were 15.39 +/- 4.61 h and 16.06 +/- 5.56 h, and of T(max) were 1.3 +/- 0.9 h and 1.4 +/- 0.7 h respectively.",[Pharmacokinetics and relative bioavailability study of roxithromycin tablet in Chinese healthy volunteers by LC-MS/MS]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20095494/),h,1.3,20990,DB00778,Roxithromycin
,20095494,T(max),"For test and reference capsule, the values of C(max) were 6 631.5 microg x L(-1) and 7 033.9 microg x L(-1) respectively, of T1/2 were 15.39 +/- 4.61 h and 16.06 +/- 5.56 h, and of T(max) were 1.3 +/- 0.9 h and 1.4 +/- 0.7 h respectively.",[Pharmacokinetics and relative bioavailability study of roxithromycin tablet in Chinese healthy volunteers by LC-MS/MS]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20095494/),h,1.4,20991,DB00778,Roxithromycin
,20095494,relative bioavailability F,The relative bioavailability F was 94.9% +/- 22.4% of tested formulation.,[Pharmacokinetics and relative bioavailability study of roxithromycin tablet in Chinese healthy volunteers by LC-MS/MS]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20095494/),%,94.9,20992,DB00778,Roxithromycin
,16970627,V(c),The estimated pharmacokinetic parameters (geometric mean) were as follows: V(c) = 2.59 l; k(10) = 0.08/h; k(12) = 0.26/h; k(21) = 0.40/h.,Pharmacokinetic/pharmacodynamic modelling of roxithromycin for the inhibitory effect of tumour necrosis factor-alpha and interleukin-6 production in dogs. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16970627/),l,2.59,29456,DB00778,Roxithromycin
,16970627,k(10),The estimated pharmacokinetic parameters (geometric mean) were as follows: V(c) = 2.59 l; k(10) = 0.08/h; k(12) = 0.26/h; k(21) = 0.40/h.,Pharmacokinetic/pharmacodynamic modelling of roxithromycin for the inhibitory effect of tumour necrosis factor-alpha and interleukin-6 production in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16970627/),1/[h],0.08,29457,DB00778,Roxithromycin
,16970627,k(12),The estimated pharmacokinetic parameters (geometric mean) were as follows: V(c) = 2.59 l; k(10) = 0.08/h; k(12) = 0.26/h; k(21) = 0.40/h.,Pharmacokinetic/pharmacodynamic modelling of roxithromycin for the inhibitory effect of tumour necrosis factor-alpha and interleukin-6 production in dogs. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16970627/),1/[h],0.26,29458,DB00778,Roxithromycin
,16970627,k(21),The estimated pharmacokinetic parameters (geometric mean) were as follows: V(c) = 2.59 l; k(10) = 0.08/h; k(12) = 0.26/h; k(21) = 0.40/h.,Pharmacokinetic/pharmacodynamic modelling of roxithromycin for the inhibitory effect of tumour necrosis factor-alpha and interleukin-6 production in dogs. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16970627/),1/[h],0.40,29459,DB00778,Roxithromycin
,16970627,k(in),"The pharmacodynamic parameters (geometric mean) for the inhibitory effect on cytokine production induced by heat-killed Staphylococcus aureus (HKSA) were for TNF-alpha (k(in) = 1.42 microg/h; k(out) = 1.10 microg/h; EC(50) > 5.69 mg/l) and for IL-6 (k(in) = 2.31 microg/h; k(out) = 2.04 microg/h; EC(50) = 21.07 mg/l) production, respectively.",Pharmacokinetic/pharmacodynamic modelling of roxithromycin for the inhibitory effect of tumour necrosis factor-alpha and interleukin-6 production in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16970627/),[μg] / [h],1.42,29460,DB00778,Roxithromycin
,16970627,k(out),"The pharmacodynamic parameters (geometric mean) for the inhibitory effect on cytokine production induced by heat-killed Staphylococcus aureus (HKSA) were for TNF-alpha (k(in) = 1.42 microg/h; k(out) = 1.10 microg/h; EC(50) > 5.69 mg/l) and for IL-6 (k(in) = 2.31 microg/h; k(out) = 2.04 microg/h; EC(50) = 21.07 mg/l) production, respectively.",Pharmacokinetic/pharmacodynamic modelling of roxithromycin for the inhibitory effect of tumour necrosis factor-alpha and interleukin-6 production in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16970627/),[μg] / [h],1.10,29461,DB00778,Roxithromycin
>,16970627,EC(50),"The pharmacodynamic parameters (geometric mean) for the inhibitory effect on cytokine production induced by heat-killed Staphylococcus aureus (HKSA) were for TNF-alpha (k(in) = 1.42 microg/h; k(out) = 1.10 microg/h; EC(50) > 5.69 mg/l) and for IL-6 (k(in) = 2.31 microg/h; k(out) = 2.04 microg/h; EC(50) = 21.07 mg/l) production, respectively.",Pharmacokinetic/pharmacodynamic modelling of roxithromycin for the inhibitory effect of tumour necrosis factor-alpha and interleukin-6 production in dogs. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16970627/),[mg] / [l],5.69,29462,DB00778,Roxithromycin
,16970627,k(in),"The pharmacodynamic parameters (geometric mean) for the inhibitory effect on cytokine production induced by heat-killed Staphylococcus aureus (HKSA) were for TNF-alpha (k(in) = 1.42 microg/h; k(out) = 1.10 microg/h; EC(50) > 5.69 mg/l) and for IL-6 (k(in) = 2.31 microg/h; k(out) = 2.04 microg/h; EC(50) = 21.07 mg/l) production, respectively.",Pharmacokinetic/pharmacodynamic modelling of roxithromycin for the inhibitory effect of tumour necrosis factor-alpha and interleukin-6 production in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16970627/),[μg] / [h],2.31,29463,DB00778,Roxithromycin
,16970627,k(out),"The pharmacodynamic parameters (geometric mean) for the inhibitory effect on cytokine production induced by heat-killed Staphylococcus aureus (HKSA) were for TNF-alpha (k(in) = 1.42 microg/h; k(out) = 1.10 microg/h; EC(50) > 5.69 mg/l) and for IL-6 (k(in) = 2.31 microg/h; k(out) = 2.04 microg/h; EC(50) = 21.07 mg/l) production, respectively.",Pharmacokinetic/pharmacodynamic modelling of roxithromycin for the inhibitory effect of tumour necrosis factor-alpha and interleukin-6 production in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16970627/),[μg] / [h],2.04,29464,DB00778,Roxithromycin
,16970627,EC(50),"The pharmacodynamic parameters (geometric mean) for the inhibitory effect on cytokine production induced by heat-killed Staphylococcus aureus (HKSA) were for TNF-alpha (k(in) = 1.42 microg/h; k(out) = 1.10 microg/h; EC(50) > 5.69 mg/l) and for IL-6 (k(in) = 2.31 microg/h; k(out) = 2.04 microg/h; EC(50) = 21.07 mg/l) production, respectively.",Pharmacokinetic/pharmacodynamic modelling of roxithromycin for the inhibitory effect of tumour necrosis factor-alpha and interleukin-6 production in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16970627/),[mg] / [l],21.07,29465,DB00778,Roxithromycin
,11751774,MICs,"Clinical isolates of S. pyogenes and S. pneumoniae (MICs 0.12 and 0.47 mg/L of azithromycin, and 0.15 and 0.60 mg/L of roxithromycin, respectively) were used.",Comparative pharmacodynamics of azithromycin and roxithromycin with S. pyogenes and S. pneumoniae in a model that simulates in vitro pharmacokinetics in human tonsils. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11751774/),[mg] / [l],0.12,31504,DB00778,Roxithromycin
,11751774,MICs,"Clinical isolates of S. pyogenes and S. pneumoniae (MICs 0.12 and 0.47 mg/L of azithromycin, and 0.15 and 0.60 mg/L of roxithromycin, respectively) were used.",Comparative pharmacodynamics of azithromycin and roxithromycin with S. pyogenes and S. pneumoniae in a model that simulates in vitro pharmacokinetics in human tonsils. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11751774/),[mg] / [l],0.47,31505,DB00778,Roxithromycin
,11751774,MICs,"Clinical isolates of S. pyogenes and S. pneumoniae (MICs 0.12 and 0.47 mg/L of azithromycin, and 0.15 and 0.60 mg/L of roxithromycin, respectively) were used.",Comparative pharmacodynamics of azithromycin and roxithromycin with S. pyogenes and S. pneumoniae in a model that simulates in vitro pharmacokinetics in human tonsils. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11751774/),[mg] / [l],0.15,31506,DB00778,Roxithromycin
,11751774,MICs,"Clinical isolates of S. pyogenes and S. pneumoniae (MICs 0.12 and 0.47 mg/L of azithromycin, and 0.15 and 0.60 mg/L of roxithromycin, respectively) were used.",Comparative pharmacodynamics of azithromycin and roxithromycin with S. pyogenes and S. pneumoniae in a model that simulates in vitro pharmacokinetics in human tonsils. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11751774/),[mg] / [l],0.60,31507,DB00778,Roxithromycin
,25559065,AUC0-36,"Study A: Geometric mean AUC0-36 for BCQB alone and co-administered with paroxetine were 474.3 and 631.3pgh/ml, respectively.",Study of pharmacokinetic interaction of paroxetine and roxithromycin on bencycloquidium bromide in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25559065/),[pgh] / [ml],474.3,33024,DB00778,Roxithromycin
,25559065,AUC0-36,"Study A: Geometric mean AUC0-36 for BCQB alone and co-administered with paroxetine were 474.3 and 631.3pgh/ml, respectively.",Study of pharmacokinetic interaction of paroxetine and roxithromycin on bencycloquidium bromide in healthy subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25559065/),[pgh] / [ml],631.3,33025,DB00778,Roxithromycin
,25559065,Cmax,Geometric mean Cmax were 187.0 and 181.2pg/ml.,Study of pharmacokinetic interaction of paroxetine and roxithromycin on bencycloquidium bromide in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25559065/),[pg] / [ml],187.0,33026,DB00778,Roxithromycin
,25559065,Cmax,Geometric mean Cmax were 187.0 and 181.2pg/ml.,Study of pharmacokinetic interaction of paroxetine and roxithromycin on bencycloquidium bromide in healthy subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25559065/),[pg] / [ml],181.2,33027,DB00778,Roxithromycin
,1881685,Serum peak level,"Serum peak level, measured at the 4th h, reached 6.60 +/- 1.15 micrograms/ml.",[Diffusion of roxithromycin in gingival tissue]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1881685/),[μg] / [ml],6.60,34141,DB00778,Roxithromycin
,1881685,tissue peak concentration,The tissue peak concentration was 4.63 +/- 1.84 micrograms/g at the 8th h.,[Diffusion of roxithromycin in gingival tissue]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1881685/),[μg] / [g],4.63,34142,DB00778,Roxithromycin
,23317671,detection limit,"The detection limit of the proposed method for the determination of ROX was as low as 0.2 pmol·L(-1) (3σ), and the relative standard deviations were less than 4.0% (n = 7).","Continuous, quantitative monitoring of roxithromycin in human saliva by flow injection chemiluminescence analysis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23317671/),[pM] / [l],0.2,63912,DB00778,Roxithromycin
,23317671,flow rate,"A complete analytical process, including sampling and washing for ROX determination, conducted at a flow rate of 2.0 mL·min(-1), was performed completely within 30 s, yielding a sample efficiency of 120 h(-1).","Continuous, quantitative monitoring of roxithromycin in human saliva by flow injection chemiluminescence analysis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23317671/),[ml] / [min],2.0,63913,DB00778,Roxithromycin
,23317671,sample efficiency,"A complete analytical process, including sampling and washing for ROX determination, conducted at a flow rate of 2.0 mL·min(-1), was performed completely within 30 s, yielding a sample efficiency of 120 h(-1).","Continuous, quantitative monitoring of roxithromycin in human saliva by flow injection chemiluminescence analysis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23317671/),1/[h],120,63914,DB00778,Roxithromycin
,23317671,recoveries,The proposed method was successfully applied to the determination of ROX in human saliva and serum samples with recoveries from 90.9% to 110.1%.,"Continuous, quantitative monitoring of roxithromycin in human saliva by flow injection chemiluminescence analysis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23317671/),%,90.9,63915,DB00778,Roxithromycin
,23317671,recoveries,The proposed method was successfully applied to the determination of ROX in human saliva and serum samples with recoveries from 90.9% to 110.1%.,"Continuous, quantitative monitoring of roxithromycin in human saliva by flow injection chemiluminescence analysis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23317671/),%,110.1,63916,DB00778,Roxithromycin
,23317671,total elimination ratio,"The continuous monitoring of ROX in human saliva after oral intake showed that the total elimination ratio was 87.1% during 24 h, and the pharmacokinetic parameters were 0.97 ± 0.18 h(-1) for the absorption rate constant K(a), 0.082 ± 0.010 h(-1) for the elimination rate constant K(e), and 8.56 ± 1.11 h for the elimination half-life time t(1/2).","Continuous, quantitative monitoring of roxithromycin in human saliva by flow injection chemiluminescence analysis. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23317671/),%,87.1,63917,DB00778,Roxithromycin
,23317671,absorption rate constant K(a),"The continuous monitoring of ROX in human saliva after oral intake showed that the total elimination ratio was 87.1% during 24 h, and the pharmacokinetic parameters were 0.97 ± 0.18 h(-1) for the absorption rate constant K(a), 0.082 ± 0.010 h(-1) for the elimination rate constant K(e), and 8.56 ± 1.11 h for the elimination half-life time t(1/2).","Continuous, quantitative monitoring of roxithromycin in human saliva by flow injection chemiluminescence analysis. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23317671/),1/[h],0.97,63918,DB00778,Roxithromycin
,23317671,elimination rate constant K(e),"The continuous monitoring of ROX in human saliva after oral intake showed that the total elimination ratio was 87.1% during 24 h, and the pharmacokinetic parameters were 0.97 ± 0.18 h(-1) for the absorption rate constant K(a), 0.082 ± 0.010 h(-1) for the elimination rate constant K(e), and 8.56 ± 1.11 h for the elimination half-life time t(1/2).","Continuous, quantitative monitoring of roxithromycin in human saliva by flow injection chemiluminescence analysis. ",k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23317671/),1/[h],0.082,63919,DB00778,Roxithromycin
,23317671,elimination half-life time t(1/2),"The continuous monitoring of ROX in human saliva after oral intake showed that the total elimination ratio was 87.1% during 24 h, and the pharmacokinetic parameters were 0.97 ± 0.18 h(-1) for the absorption rate constant K(a), 0.082 ± 0.010 h(-1) for the elimination rate constant K(e), and 8.56 ± 1.11 h for the elimination half-life time t(1/2).","Continuous, quantitative monitoring of roxithromycin in human saliva by flow injection chemiluminescence analysis. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23317671/),h,8.56,63920,DB00778,Roxithromycin
,21749408,maximum plasma concentration (C(max) ),"After p.o. administration, the maximum plasma concentration (C(max) ) was 0.20 ± 0.05 μg/mL at 3.75 ± 0.71 h.",Pharmacokinetics of tulathromycin and its metabolite in swine administered with an intravenous bolus injection and a single gavage. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21749408/),[μg] / [ml],0.20,74352,DB00778,Roxithromycin
,21749408,terminal half-life (t(1/2λz) ),"The terminal half-life (t(1/2λz) ) in plasma was 78.7 ± 6.75 h, and plasma clearance (Cl/F) was 1.14 ± 0.28 L/h/kg.",Pharmacokinetics of tulathromycin and its metabolite in swine administered with an intravenous bolus injection and a single gavage. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21749408/),h,78.7,74353,DB00778,Roxithromycin
,21749408,plasma clearance (Cl/F),"The terminal half-life (t(1/2λz) ) in plasma was 78.7 ± 6.75 h, and plasma clearance (Cl/F) was 1.14 ± 0.28 L/h/kg.",Pharmacokinetics of tulathromycin and its metabolite in swine administered with an intravenous bolus injection and a single gavage. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21749408/),[l] / [h·kg],1.14,74354,DB00778,Roxithromycin
,21749408,plasma clearance (Cl),"After i.v. injection, plasma clearance (Cl) was 0.580 ± 0.170 L/h/kg, the volume of distribution (Vz) was 64.3 ± 21.2 L/kg, and the t(1/2λz) was 76.5 ± 13.4 h.",Pharmacokinetics of tulathromycin and its metabolite in swine administered with an intravenous bolus injection and a single gavage. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21749408/),[l] / [h·kg],0.580,74355,DB00778,Roxithromycin
,21749408,volume of distribution (Vz),"After i.v. injection, plasma clearance (Cl) was 0.580 ± 0.170 L/h/kg, the volume of distribution (Vz) was 64.3 ± 21.2 L/kg, and the t(1/2λz) was 76.5 ± 13.4 h.",Pharmacokinetics of tulathromycin and its metabolite in swine administered with an intravenous bolus injection and a single gavage. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21749408/),[l] / [kg],64.3,74356,DB00778,Roxithromycin
,21749408,t(1/2λz),"After i.v. injection, plasma clearance (Cl) was 0.580 ± 0.170 L/h/kg, the volume of distribution (Vz) was 64.3 ± 21.2 L/kg, and the t(1/2λz) was 76.5 ± 13.4 h.",Pharmacokinetics of tulathromycin and its metabolite in swine administered with an intravenous bolus injection and a single gavage. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21749408/),h,76.5,74357,DB00778,Roxithromycin
,21749408,systemic bioavailability,"Following p.o. administration to pigs at 2.5 mg/kg b.w., tulathromycin was rapidly absorbed and the systemic bioavailability was 51.1 ± 10.2.",Pharmacokinetics of tulathromycin and its metabolite in swine administered with an intravenous bolus injection and a single gavage. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21749408/),,51.1,74358,DB00778,Roxithromycin
greater,2656049,tissue/serum concentration ratios,"Macrolides are highly liposoluble and consequently penetrate well into tissue, especially bronchial secretions, prostatic tissue, middle ear exudates and bone tissues, as evidenced by tissue/serum concentration ratios greater than 1.",Clinical pharmacokinetic properties of the macrolide antibiotics. Effects of age and various pathophysiological states (Part I). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2656049/),,1,79287,DB00778,Roxithromycin
,2656049,protein-bound fraction,"The lowest values of protein-bound fraction are observed for midecamycin and josamycin (about 15%), and intermediate values are reported for spiramycin and miocamycin.",Clinical pharmacokinetic properties of the macrolide antibiotics. Effects of age and various pathophysiological states (Part I). ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2656049/),%,15,79288,DB00778,Roxithromycin
,2656049,t1/2,"Plasma half-life (t1/2) values vary for the macrolides described: erythromycin, oleandomycin, josamycin and miocamycin have a t1/2 ranging from 1 to 2 hours; spiramycin, erythromycin stearate, the mercaptosuccinate salt of propionyl erythromycin and rosaramicin have an intermediate t1/2 (about 7, 6.5, 5 and 4.5 hours, respectively); the newer semisynthetic compounds roxithromycin and azithromycin are characterised by high t1/2 values (i.e. 11 and 41 hours, respectively).",Clinical pharmacokinetic properties of the macrolide antibiotics. Effects of age and various pathophysiological states (Part I). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2656049/),h,1 to 2,79289,DB00778,Roxithromycin
,2656049,t1/2,"Plasma half-life (t1/2) values vary for the macrolides described: erythromycin, oleandomycin, josamycin and miocamycin have a t1/2 ranging from 1 to 2 hours; spiramycin, erythromycin stearate, the mercaptosuccinate salt of propionyl erythromycin and rosaramicin have an intermediate t1/2 (about 7, 6.5, 5 and 4.5 hours, respectively); the newer semisynthetic compounds roxithromycin and azithromycin are characterised by high t1/2 values (i.e. 11 and 41 hours, respectively).",Clinical pharmacokinetic properties of the macrolide antibiotics. Effects of age and various pathophysiological states (Part I). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2656049/),h,7,79290,DB00778,Roxithromycin
,2656049,t1/2,"Plasma half-life (t1/2) values vary for the macrolides described: erythromycin, oleandomycin, josamycin and miocamycin have a t1/2 ranging from 1 to 2 hours; spiramycin, erythromycin stearate, the mercaptosuccinate salt of propionyl erythromycin and rosaramicin have an intermediate t1/2 (about 7, 6.5, 5 and 4.5 hours, respectively); the newer semisynthetic compounds roxithromycin and azithromycin are characterised by high t1/2 values (i.e. 11 and 41 hours, respectively).",Clinical pharmacokinetic properties of the macrolide antibiotics. Effects of age and various pathophysiological states (Part I). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2656049/),h,6.5,79291,DB00778,Roxithromycin
,2656049,t1/2,"Plasma half-life (t1/2) values vary for the macrolides described: erythromycin, oleandomycin, josamycin and miocamycin have a t1/2 ranging from 1 to 2 hours; spiramycin, erythromycin stearate, the mercaptosuccinate salt of propionyl erythromycin and rosaramicin have an intermediate t1/2 (about 7, 6.5, 5 and 4.5 hours, respectively); the newer semisynthetic compounds roxithromycin and azithromycin are characterised by high t1/2 values (i.e. 11 and 41 hours, respectively).",Clinical pharmacokinetic properties of the macrolide antibiotics. Effects of age and various pathophysiological states (Part I). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2656049/),h,5,79292,DB00778,Roxithromycin
,2656049,t1/2,"Plasma half-life (t1/2) values vary for the macrolides described: erythromycin, oleandomycin, josamycin and miocamycin have a t1/2 ranging from 1 to 2 hours; spiramycin, erythromycin stearate, the mercaptosuccinate salt of propionyl erythromycin and rosaramicin have an intermediate t1/2 (about 7, 6.5, 5 and 4.5 hours, respectively); the newer semisynthetic compounds roxithromycin and azithromycin are characterised by high t1/2 values (i.e. 11 and 41 hours, respectively).",Clinical pharmacokinetic properties of the macrolide antibiotics. Effects of age and various pathophysiological states (Part I). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2656049/),h,4.5,79293,DB00778,Roxithromycin
,2656049,t1/2,"Plasma half-life (t1/2) values vary for the macrolides described: erythromycin, oleandomycin, josamycin and miocamycin have a t1/2 ranging from 1 to 2 hours; spiramycin, erythromycin stearate, the mercaptosuccinate salt of propionyl erythromycin and rosaramicin have an intermediate t1/2 (about 7, 6.5, 5 and 4.5 hours, respectively); the newer semisynthetic compounds roxithromycin and azithromycin are characterised by high t1/2 values (i.e. 11 and 41 hours, respectively).",Clinical pharmacokinetic properties of the macrolide antibiotics. Effects of age and various pathophysiological states (Part I). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2656049/),h,11,79294,DB00778,Roxithromycin
,2656049,t1/2,"Plasma half-life (t1/2) values vary for the macrolides described: erythromycin, oleandomycin, josamycin and miocamycin have a t1/2 ranging from 1 to 2 hours; spiramycin, erythromycin stearate, the mercaptosuccinate salt of propionyl erythromycin and rosaramicin have an intermediate t1/2 (about 7, 6.5, 5 and 4.5 hours, respectively); the newer semisynthetic compounds roxithromycin and azithromycin are characterised by high t1/2 values (i.e. 11 and 41 hours, respectively).",Clinical pharmacokinetic properties of the macrolide antibiotics. Effects of age and various pathophysiological states (Part I). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2656049/),h,41,79295,DB00778,Roxithromycin
,3481332,minimal inhibitory concentrations (MICs),"The minimal inhibitory concentrations (MICs) against Streptococcus pneumoniae range between 1 and 2 mg/L. MICs of roxithromycin (RU 28965) against S. pneumoniae range between 0.004 and 0.03 mg/L, but Gram-negative bacilli are resistant.",Bactericidal activity of ofloxacin versus roxithromycin in the treatment of Streptococcus pneumoniae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3481332/),[mg] / [l],1 and 2,81680,DB00778,Roxithromycin
,3481332,MICs,"The minimal inhibitory concentrations (MICs) against Streptococcus pneumoniae range between 1 and 2 mg/L. MICs of roxithromycin (RU 28965) against S. pneumoniae range between 0.004 and 0.03 mg/L, but Gram-negative bacilli are resistant.",Bactericidal activity of ofloxacin versus roxithromycin in the treatment of Streptococcus pneumoniae. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3481332/),[mg] / [l],0.004 and 0.03,81681,DB00778,Roxithromycin
,3481332,Initial concentrations,"Initial concentrations were 10 mg/L for roxithromycin and 2 mg/L for ofloxacin, and the half-life was 6 hours for both compounds.",Bactericidal activity of ofloxacin versus roxithromycin in the treatment of Streptococcus pneumoniae. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3481332/),[mg] / [l],10,81682,DB00778,Roxithromycin
,3481332,Initial concentrations,"Initial concentrations were 10 mg/L for roxithromycin and 2 mg/L for ofloxacin, and the half-life was 6 hours for both compounds.",Bactericidal activity of ofloxacin versus roxithromycin in the treatment of Streptococcus pneumoniae. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3481332/),[mg] / [l],2,81683,DB00778,Roxithromycin
,3481332,half-life,"Initial concentrations were 10 mg/L for roxithromycin and 2 mg/L for ofloxacin, and the half-life was 6 hours for both compounds.",Bactericidal activity of ofloxacin versus roxithromycin in the treatment of Streptococcus pneumoniae. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3481332/),h,6,81684,DB00778,Roxithromycin
,1617928,peak serum level,"The peak serum level, reached 4 hr after dosing, was 6.60 +/- 1.15 micrograms/ml.",Penetration of roxithromycin into gingival tissue. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1617928/),[μg] / [ml],6.60,82879,DB00778,Roxithromycin
,1617928,peak tissue level,The peak tissue level was 4.63 +/- 1.84 micrograms/g and was reached after 8 hr.,Penetration of roxithromycin into gingival tissue. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1617928/),[μg] / [g],4.63,82880,DB00778,Roxithromycin
,16724928,detection limit,The increment of chemiluminescence intensity was linear with roxithromycin concentration in the range 1.0-1000 pg ml(-1) with the detection limit of 0.3 pg ml(-1) (3sigma).,In vitro monitoring picogram roxithromycin in human urine using flow injection chemiluminescence procedure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16724928/),[pg] / [ml],0.3,83815,DB00778,Roxithromycin
,16724928,flow rate,"At a flow rate of 2.0 ml min(-1), a complete analytical process could be performed within 0.5 min, including sampling and washing, with a relative standard deviation of less than 5%.",In vitro monitoring picogram roxithromycin in human urine using flow injection chemiluminescence procedure. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16724928/),[ml] / [min],2.0,83816,DB00778,Roxithromycin
,16724928,excretive ratio,"The proposed procedure was applied successfully in the monitoring of roxithromycin in human urine without any pre-treatment procedures and it was found that roxithromycin in urine reached its maximum after orally administrated for two hours, presenting an excretive ratio of 4.6% in 12 h.",In vitro monitoring picogram roxithromycin in human urine using flow injection chemiluminescence procedure. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16724928/),%,4.6,83817,DB00778,Roxithromycin
,16724928,total elimination rate constant k,"With urinary excretion rate method, the total elimination rate constant k and half-life time t(1/2) of roxithomycin was calculated, which was 0.1831, 3.785 h.",In vitro monitoring picogram roxithromycin in human urine using flow injection chemiluminescence procedure. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16724928/),h,0.1831,83818,DB00778,Roxithromycin
,16724928,half-life time t(1/2),"With urinary excretion rate method, the total elimination rate constant k and half-life time t(1/2) of roxithomycin was calculated, which was 0.1831, 3.785 h.",In vitro monitoring picogram roxithromycin in human urine using flow injection chemiluminescence procedure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16724928/),h,3.785,83819,DB00778,Roxithromycin
,7995324,area under the plasma midazolam concentration-time curve,Roxithromycin administration significantly increased the area under the plasma midazolam concentration-time curve from 8.3 to 12.2 micrograms.,A pharmacokinetic interaction between roxithromycin and midazolam. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7995324/),μg,8.3,91844,DB00778,Roxithromycin
,7995324,area under the plasma midazolam concentration-time curve,Roxithromycin administration significantly increased the area under the plasma midazolam concentration-time curve from 8.3 to 12.2 micrograms.,A pharmacokinetic interaction between roxithromycin and midazolam. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7995324/),μg,12.2,91845,DB00778,Roxithromycin
,7995324,elimination half-lives,ml-1.min and the elimination half-lives from 1.7 to 2.2 h.,A pharmacokinetic interaction between roxithromycin and midazolam. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7995324/),h,1.7 to 2.2,91846,DB00778,Roxithromycin
,18968261,total analysis time per sample,This method showed excellent precision (RSD 3.8% at 0.1 mug ml(-1)) and accuracy (+/-2%) with the total analysis time per sample of 30 min.,Column-switching high-performance liquid chromatographic determination of clarithromycin in human plasma with electrochemical detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18968261/),min,30,110138,DB00778,Roxithromycin
,8539071,elimination half-life,"Compared to reference compounds such as erythromycin or roxithromycin, pharmacokinetic parameters of azithromycin are characterized by: (i) much lower serum concentrations; (ii) a much longer elimination half-life (48-96 h); (iii) high and persistent tissue concentrations.",[Azithromycin: tissue pharmacology]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8539071/),h,48-96,120014,DB00778,Roxithromycin
,3323171,half-life (T1/2),The drug is eliminated with a half-life (T1/2) of about 10 h.,Roxithromycin: a pharmacokinetic review of a macrolide. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3323171/),h,10,120337,DB00778,Roxithromycin
,11868800,maximum concentration (Cmax),"The mean (+/- SD) pharmacokinetic parameters of lovastatin lactone with and without roxithromycin were maximum concentration (Cmax) 8.49+/-6.80/16.3+/-9.4 ng ml(-1), time to Cmax (tmax) 1.8+/-0.4/1.7+/-0.6 h, terminal plasma half-life (t1/2) 4.3+/-2.0/3.7+/-2.5 h, area under the plasma concentration-time curve from zero to infinity (AUC0-infinity) 53+/-60/85+/-67 ng ml(-1) h.",Effect of roxithromycin on the pharmacokinetics of lovastatin in volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11868800/),[ng] / [ml],8.49,124585,DB00778,Roxithromycin
,11868800,maximum concentration (Cmax),"The mean (+/- SD) pharmacokinetic parameters of lovastatin lactone with and without roxithromycin were maximum concentration (Cmax) 8.49+/-6.80/16.3+/-9.4 ng ml(-1), time to Cmax (tmax) 1.8+/-0.4/1.7+/-0.6 h, terminal plasma half-life (t1/2) 4.3+/-2.0/3.7+/-2.5 h, area under the plasma concentration-time curve from zero to infinity (AUC0-infinity) 53+/-60/85+/-67 ng ml(-1) h.",Effect of roxithromycin on the pharmacokinetics of lovastatin in volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11868800/),[ng] / [ml],16.3,124586,DB00778,Roxithromycin
,11868800,time to Cmax (tmax),"The mean (+/- SD) pharmacokinetic parameters of lovastatin lactone with and without roxithromycin were maximum concentration (Cmax) 8.49+/-6.80/16.3+/-9.4 ng ml(-1), time to Cmax (tmax) 1.8+/-0.4/1.7+/-0.6 h, terminal plasma half-life (t1/2) 4.3+/-2.0/3.7+/-2.5 h, area under the plasma concentration-time curve from zero to infinity (AUC0-infinity) 53+/-60/85+/-67 ng ml(-1) h.",Effect of roxithromycin on the pharmacokinetics of lovastatin in volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11868800/),h,1.8,124587,DB00778,Roxithromycin
,11868800,time to Cmax (tmax),"The mean (+/- SD) pharmacokinetic parameters of lovastatin lactone with and without roxithromycin were maximum concentration (Cmax) 8.49+/-6.80/16.3+/-9.4 ng ml(-1), time to Cmax (tmax) 1.8+/-0.4/1.7+/-0.6 h, terminal plasma half-life (t1/2) 4.3+/-2.0/3.7+/-2.5 h, area under the plasma concentration-time curve from zero to infinity (AUC0-infinity) 53+/-60/85+/-67 ng ml(-1) h.",Effect of roxithromycin on the pharmacokinetics of lovastatin in volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11868800/),h,1.7,124588,DB00778,Roxithromycin
,11868800,terminal plasma half-life (t1/2),"The mean (+/- SD) pharmacokinetic parameters of lovastatin lactone with and without roxithromycin were maximum concentration (Cmax) 8.49+/-6.80/16.3+/-9.4 ng ml(-1), time to Cmax (tmax) 1.8+/-0.4/1.7+/-0.6 h, terminal plasma half-life (t1/2) 4.3+/-2.0/3.7+/-2.5 h, area under the plasma concentration-time curve from zero to infinity (AUC0-infinity) 53+/-60/85+/-67 ng ml(-1) h.",Effect of roxithromycin on the pharmacokinetics of lovastatin in volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11868800/),h,4.3,124589,DB00778,Roxithromycin
,11868800,terminal plasma half-life (t1/2),"The mean (+/- SD) pharmacokinetic parameters of lovastatin lactone with and without roxithromycin were maximum concentration (Cmax) 8.49+/-6.80/16.3+/-9.4 ng ml(-1), time to Cmax (tmax) 1.8+/-0.4/1.7+/-0.6 h, terminal plasma half-life (t1/2) 4.3+/-2.0/3.7+/-2.5 h, area under the plasma concentration-time curve from zero to infinity (AUC0-infinity) 53+/-60/85+/-67 ng ml(-1) h.",Effect of roxithromycin on the pharmacokinetics of lovastatin in volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11868800/),h,3.7,124590,DB00778,Roxithromycin
,11868800,area under the plasma concentration-time curve from zero to infinity (AUC0-infinity),"The mean (+/- SD) pharmacokinetic parameters of lovastatin lactone with and without roxithromycin were maximum concentration (Cmax) 8.49+/-6.80/16.3+/-9.4 ng ml(-1), time to Cmax (tmax) 1.8+/-0.4/1.7+/-0.6 h, terminal plasma half-life (t1/2) 4.3+/-2.0/3.7+/-2.5 h, area under the plasma concentration-time curve from zero to infinity (AUC0-infinity) 53+/-60/85+/-67 ng ml(-1) h.",Effect of roxithromycin on the pharmacokinetics of lovastatin in volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11868800/),[h·ng] / [ml],53,124591,DB00778,Roxithromycin
,11868800,area under the plasma concentration-time curve from zero to infinity (AUC0-infinity),"The mean (+/- SD) pharmacokinetic parameters of lovastatin lactone with and without roxithromycin were maximum concentration (Cmax) 8.49+/-6.80/16.3+/-9.4 ng ml(-1), time to Cmax (tmax) 1.8+/-0.4/1.7+/-0.6 h, terminal plasma half-life (t1/2) 4.3+/-2.0/3.7+/-2.5 h, area under the plasma concentration-time curve from zero to infinity (AUC0-infinity) 53+/-60/85+/-67 ng ml(-1) h.",Effect of roxithromycin on the pharmacokinetics of lovastatin in volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11868800/),[h·ng] / [ml],85,124592,DB00778,Roxithromycin
,11868800,Cmax,"The respective parameters of lovastatin acid were Cmax 24.6+/-13.4/17.8+/-11.0 ng ml(-1), tmax 3.7+/-1.1/4.1+/-0.7 h, t1/2 3.2+/-2.5/4.3+/-2.8 h, AUC0-infinity 149+/-123/105+/-58 ng ml(-1) h.",Effect of roxithromycin on the pharmacokinetics of lovastatin in volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11868800/),[ng] / [ml],24.6,124593,DB00778,Roxithromycin
,11868800,Cmax,"The respective parameters of lovastatin acid were Cmax 24.6+/-13.4/17.8+/-11.0 ng ml(-1), tmax 3.7+/-1.1/4.1+/-0.7 h, t1/2 3.2+/-2.5/4.3+/-2.8 h, AUC0-infinity 149+/-123/105+/-58 ng ml(-1) h.",Effect of roxithromycin on the pharmacokinetics of lovastatin in volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11868800/),[ng] / [ml],17.8,124594,DB00778,Roxithromycin
,11868800,tmax,"The respective parameters of lovastatin acid were Cmax 24.6+/-13.4/17.8+/-11.0 ng ml(-1), tmax 3.7+/-1.1/4.1+/-0.7 h, t1/2 3.2+/-2.5/4.3+/-2.8 h, AUC0-infinity 149+/-123/105+/-58 ng ml(-1) h.",Effect of roxithromycin on the pharmacokinetics of lovastatin in volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11868800/),h,3.7,124595,DB00778,Roxithromycin
,11868800,tmax,"The respective parameters of lovastatin acid were Cmax 24.6+/-13.4/17.8+/-11.0 ng ml(-1), tmax 3.7+/-1.1/4.1+/-0.7 h, t1/2 3.2+/-2.5/4.3+/-2.8 h, AUC0-infinity 149+/-123/105+/-58 ng ml(-1) h.",Effect of roxithromycin on the pharmacokinetics of lovastatin in volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11868800/),h,4.1,124596,DB00778,Roxithromycin
,11868800,t1/2,"The respective parameters of lovastatin acid were Cmax 24.6+/-13.4/17.8+/-11.0 ng ml(-1), tmax 3.7+/-1.1/4.1+/-0.7 h, t1/2 3.2+/-2.5/4.3+/-2.8 h, AUC0-infinity 149+/-123/105+/-58 ng ml(-1) h.",Effect of roxithromycin on the pharmacokinetics of lovastatin in volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11868800/),h,3.2,124597,DB00778,Roxithromycin
,11868800,t1/2,"The respective parameters of lovastatin acid were Cmax 24.6+/-13.4/17.8+/-11.0 ng ml(-1), tmax 3.7+/-1.1/4.1+/-0.7 h, t1/2 3.2+/-2.5/4.3+/-2.8 h, AUC0-infinity 149+/-123/105+/-58 ng ml(-1) h.",Effect of roxithromycin on the pharmacokinetics of lovastatin in volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11868800/),h,4.3,124598,DB00778,Roxithromycin
,11868800,AUC0-infinity,"The respective parameters of lovastatin acid were Cmax 24.6+/-13.4/17.8+/-11.0 ng ml(-1), tmax 3.7+/-1.1/4.1+/-0.7 h, t1/2 3.2+/-2.5/4.3+/-2.8 h, AUC0-infinity 149+/-123/105+/-58 ng ml(-1) h.",Effect of roxithromycin on the pharmacokinetics of lovastatin in volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11868800/),[h·ng] / [ml],149,124599,DB00778,Roxithromycin
,11868800,AUC0-infinity,"The respective parameters of lovastatin acid were Cmax 24.6+/-13.4/17.8+/-11.0 ng ml(-1), tmax 3.7+/-1.1/4.1+/-0.7 h, t1/2 3.2+/-2.5/4.3+/-2.8 h, AUC0-infinity 149+/-123/105+/-58 ng ml(-1) h.",Effect of roxithromycin on the pharmacokinetics of lovastatin in volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11868800/),[h·ng] / [ml],105,124600,DB00778,Roxithromycin
,18639501,flow rate,The flow rate was 0.22 mL/min and the total run time (injection to injection) was less than 3 min.,Simplified method for determination of clarithromycin in human plasma using protein precipitation in a 96-well format and liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18639501/),[ml] / [min],0.22,127039,DB00778,Roxithromycin
less,18639501,total run time,The flow rate was 0.22 mL/min and the total run time (injection to injection) was less than 3 min.,Simplified method for determination of clarithromycin in human plasma using protein precipitation in a 96-well format and liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18639501/),min,3,127040,DB00778,Roxithromycin
,8396089,AUC,"In an early abscess (18 h post-challenge), azithromycin penetration into inflammatory fluid was enhanced (AUC of 351 vs 130 mg.h/kg) and residence prolonged relative to an inflammation control (half-life of 88 vs 27 h).","Comparison of azithromycin, roxithromycin, and cephalexin penetration kinetics in early and mature abscesses. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8396089/),[h·mg] / [kg],351,135723,DB00778,Roxithromycin
,8396089,AUC,"In an early abscess (18 h post-challenge), azithromycin penetration into inflammatory fluid was enhanced (AUC of 351 vs 130 mg.h/kg) and residence prolonged relative to an inflammation control (half-life of 88 vs 27 h).","Comparison of azithromycin, roxithromycin, and cephalexin penetration kinetics in early and mature abscesses. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8396089/),[h·mg] / [kg],130,135724,DB00778,Roxithromycin
,8396089,half-life,"In an early abscess (18 h post-challenge), azithromycin penetration into inflammatory fluid was enhanced (AUC of 351 vs 130 mg.h/kg) and residence prolonged relative to an inflammation control (half-life of 88 vs 27 h).","Comparison of azithromycin, roxithromycin, and cephalexin penetration kinetics in early and mature abscesses. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8396089/),h,88,135725,DB00778,Roxithromycin
,8396089,half-life,"In an early abscess (18 h post-challenge), azithromycin penetration into inflammatory fluid was enhanced (AUC of 351 vs 130 mg.h/kg) and residence prolonged relative to an inflammation control (half-life of 88 vs 27 h).","Comparison of azithromycin, roxithromycin, and cephalexin penetration kinetics in early and mature abscesses. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8396089/),h,27,135726,DB00778,Roxithromycin
,1827103,peak concentrations,"Clarithromycin reached peak tissue levels 4 h after administration and achieved mean peak concentrations of 8.32 mg/kg +/- 2.57 in nasal mucosa, 6.47 mg/kg +/- 2.8 in tonsil, and 17.47 mg/kg +/- 3.29 in lung tissue.","The diffusion of clarithromycin and roxithromycin into nasal mucosa, tonsil and lung in humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1827103/),[mg] / [kg],8.32,138105,DB00778,Roxithromycin
,1827103,peak concentrations,"Clarithromycin reached peak tissue levels 4 h after administration and achieved mean peak concentrations of 8.32 mg/kg +/- 2.57 in nasal mucosa, 6.47 mg/kg +/- 2.8 in tonsil, and 17.47 mg/kg +/- 3.29 in lung tissue.","The diffusion of clarithromycin and roxithromycin into nasal mucosa, tonsil and lung in humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1827103/),[mg] / [kg],6.47,138106,DB00778,Roxithromycin
,1827103,peak concentrations,"Clarithromycin reached peak tissue levels 4 h after administration and achieved mean peak concentrations of 8.32 mg/kg +/- 2.57 in nasal mucosa, 6.47 mg/kg +/- 2.8 in tonsil, and 17.47 mg/kg +/- 3.29 in lung tissue.","The diffusion of clarithromycin and roxithromycin into nasal mucosa, tonsil and lung in humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1827103/),[mg] / [kg],17.47,138107,DB00778,Roxithromycin
,1827103,peak concentrations,"Roxithromycin reached peak tissue levels between 4 and 6 h after administration, achieving mean peak concentrations of 1.78 mg/kg +/- 0.73 in nasal mucosa, 2.2 mg/kg +/- 1.21 in tonsil, and 2.14 mg/kg +/- 0.87 in lung tissue.","The diffusion of clarithromycin and roxithromycin into nasal mucosa, tonsil and lung in humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1827103/),[mg] / [kg],1.78,138108,DB00778,Roxithromycin
,1827103,peak concentrations,"Roxithromycin reached peak tissue levels between 4 and 6 h after administration, achieving mean peak concentrations of 1.78 mg/kg +/- 0.73 in nasal mucosa, 2.2 mg/kg +/- 1.21 in tonsil, and 2.14 mg/kg +/- 0.87 in lung tissue.","The diffusion of clarithromycin and roxithromycin into nasal mucosa, tonsil and lung in humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1827103/),[mg] / [kg],2.2,138109,DB00778,Roxithromycin
,1827103,peak concentrations,"Roxithromycin reached peak tissue levels between 4 and 6 h after administration, achieving mean peak concentrations of 1.78 mg/kg +/- 0.73 in nasal mucosa, 2.2 mg/kg +/- 1.21 in tonsil, and 2.14 mg/kg +/- 0.87 in lung tissue.","The diffusion of clarithromycin and roxithromycin into nasal mucosa, tonsil and lung in humans. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1827103/),[mg] / [kg],2.14,138110,DB00778,Roxithromycin
,16416302,k (inact),All five macrolides inactivated testosterone 6beta-hydroxylation by HLM and recombinant CYP3A4 with k (inact) values in the range of 0.023 to 0.058 min(-1).,Quantitative prediction of macrolide drug-drug interaction potential from in vitro studies using testosterone as the human cytochrome P4503A substrate. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16416302/),1/[min],0.023 to 0.058,155592,DB00778,Roxithromycin
,15761061,degradation half-time,"The degradation half-time of roxithromycin in simulated gastric fluid was 0.23 h, and three main degradation products were characterized.",Impact of pharmaceutical dosage forms on the pharmacokinetics of roxithromycin in healthy human volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15761061/),h,0.23,157877,DB00778,Roxithromycin
,20036479,flow rate,"Following a deproteinization procedure, the samples were eluted isocratically at a flow rate of 0.3mL/min utilizing a mobile phase containing of 10mM ammonium acetate (adjusted pH to 5.2 with 0.1% acetic acid)-methanol (18:82, v/v) and a SHISEIDO CAPCELL PAK C(18) (3.0mmx75mm, 3microm).","Rapid, sensitive and selective liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the quantification of topically applied azithromycin in rabbit conjunctiva tissues. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20036479/),[ml] / [min],0.3,158450,DB00778,Roxithromycin
,3323170,elimination half-life,"Its elimination half-life is also longer, about 12 h compared to 2-3 h for erythromycin.",Comparative pharmacokinetics of macrolides. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3323170/),h,12,158944,DB00778,Roxithromycin
,3323170,elimination half-life,"Its elimination half-life is also longer, about 12 h compared to 2-3 h for erythromycin.",Comparative pharmacokinetics of macrolides. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3323170/),h,2-3,158945,DB00778,Roxithromycin
,3662470,serum,"The mean serum and blister fluid elimination half-lives on day 3 were 13.2 and 12.5 h, respectively.",Pharmacokinetics and tissue penetration of roxithromycin after multiple dosing. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3662470/),h,13.2,162676,DB00778,Roxithromycin
,3662470,fluid elimination half-lives,"The mean serum and blister fluid elimination half-lives on day 3 were 13.2 and 12.5 h, respectively.",Pharmacokinetics and tissue penetration of roxithromycin after multiple dosing. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3662470/),h,12.5,162677,DB00778,Roxithromycin
,9579709,MICs,The range of MICs was 0.12-0.5 mg/L for both roxithromycin and erythromycin.,The comparative in-vitro activity of roxithromycin and other antibiotics against Bordetella pertussis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9579709/),[mg] / [l],0.12-0.5,162953,DB00778,Roxithromycin
,9579709,MBC,"Roxithromycin was bactericidal, with an MBC of 1 mg/L (as compared with 0.5 mg/L for erythromycin).",The comparative in-vitro activity of roxithromycin and other antibiotics against Bordetella pertussis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9579709/),[mg] / [l],1,162954,DB00778,Roxithromycin
,9579709,MBC,"Roxithromycin was bactericidal, with an MBC of 1 mg/L (as compared with 0.5 mg/L for erythromycin).",The comparative in-vitro activity of roxithromycin and other antibiotics against Bordetella pertussis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9579709/),[mg] / [l],0.5,162955,DB00778,Roxithromycin
>,28039274,f AUC/MIC ratio,These pharmacokinetic differences translated to significantly lower target attainment ( f AUC/MIC ratio >20) with a 300 mg daily regimen at MICs of 0.5 and 1 mg/L (51% and 7%) compared with patients receiving 150 mg twice daily (82% and 54%).,Population-based meta-analysis of roxithromycin pharmacokinetics: dosing implications of saturable absorption and protein binding. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28039274/),,20,164474,DB00778,Roxithromycin
,28039274,MICs,These pharmacokinetic differences translated to significantly lower target attainment ( f AUC/MIC ratio >20) with a 300 mg daily regimen at MICs of 0.5 and 1 mg/L (51% and 7%) compared with patients receiving 150 mg twice daily (82% and 54%).,Population-based meta-analysis of roxithromycin pharmacokinetics: dosing implications of saturable absorption and protein binding. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28039274/),[mg] / [l],0.5,164475,DB00778,Roxithromycin
,28039274,MICs,These pharmacokinetic differences translated to significantly lower target attainment ( f AUC/MIC ratio >20) with a 300 mg daily regimen at MICs of 0.5 and 1 mg/L (51% and 7%) compared with patients receiving 150 mg twice daily (82% and 54%).,Population-based meta-analysis of roxithromycin pharmacokinetics: dosing implications of saturable absorption and protein binding. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28039274/),[mg] / [l],1,164476,DB00778,Roxithromycin
,28039274,MICs,These pharmacokinetic differences translated to significantly lower target attainment ( f AUC/MIC ratio >20) with a 300 mg daily regimen at MICs of 0.5 and 1 mg/L (51% and 7%) compared with patients receiving 150 mg twice daily (82% and 54%).,Population-based meta-analysis of roxithromycin pharmacokinetics: dosing implications of saturable absorption and protein binding. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28039274/),,7,164477,DB00778,Roxithromycin
≥,28039274,target,"Roxithromycin displays saturable absorption and protein binding leading to lower exposure and lower target attainment at MICs ≥0.5 mg/L with widely used once-daily dosing regimens, indicating that twice-daily regimens may be preferable for pathogens less susceptible to roxithromycin.",Population-based meta-analysis of roxithromycin pharmacokinetics: dosing implications of saturable absorption and protein binding. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28039274/),[mg] / [l],0.5,164478,DB00778,Roxithromycin
,19071882,plasma-protein binding,"Although telithromycin and cethromycin show plasma-protein binding of 90%, they have excellent tissue penetration, as indicated by volumes of distribution of about 500 L and high intracellular concentrations.",Ketolides--the modern relatives of macrolides : the pharmacokinetic perspective. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19071882/),%,90,171376,DB00778,Roxithromycin
,19071882,volumes of distribution,"Although telithromycin and cethromycin show plasma-protein binding of 90%, they have excellent tissue penetration, as indicated by volumes of distribution of about 500 L and high intracellular concentrations.",Ketolides--the modern relatives of macrolides : the pharmacokinetic perspective. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19071882/),l,500,171377,DB00778,Roxithromycin
,16091946,Limit of quantification,Limit of quantification was 2.55 ng mL(-1).,Validated HPLC-MS-MS method for determination of azithromycin in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16091946/),[ng] / [ml],2.55,180684,DB00778,Roxithromycin
,1399928,tissue/serum ratios,The mean epididymal concentrations were 6.48 +/- 4.88 and 5.98 +/- 3.92 mg/kg for left and right epididymis respectively and the corresponding mean tissue/serum ratios 0.88 +/- 0.57 and 0.84 +/- 0.53.,Disposition of roxithromycin in the epididymis after repeated oral administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1399928/),,0.88,181943,DB00778,Roxithromycin
,1399928,tissue/serum ratios,The mean epididymal concentrations were 6.48 +/- 4.88 and 5.98 +/- 3.92 mg/kg for left and right epididymis respectively and the corresponding mean tissue/serum ratios 0.88 +/- 0.57 and 0.84 +/- 0.53.,Disposition of roxithromycin in the epididymis after repeated oral administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1399928/),,0.84,181944,DB00778,Roxithromycin
,1399928,MIC90s,"The concentrations observed in this study in serum and tissue were greater than the MIC90s for Chlamydia trachomatis (0.25 to 1 mg/L), and Ureaplasma urealyticum (0.5 mg/L).",Disposition of roxithromycin in the epididymis after repeated oral administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1399928/),[mg] / [l],0.25 to 1,181945,DB00778,Roxithromycin
,1399928,MIC90s,"The concentrations observed in this study in serum and tissue were greater than the MIC90s for Chlamydia trachomatis (0.25 to 1 mg/L), and Ureaplasma urealyticum (0.5 mg/L).",Disposition of roxithromycin in the epididymis after repeated oral administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1399928/),[mg] / [l],0.5,181946,DB00778,Roxithromycin
,7782117,total elimination half-life,"With the use of improved analytical methodology, a stable and prolonged total elimination half-life of roxithromycin of about 19 h was demonstrated at steady state in healthy adults with a 300 mg once daily dosage regimen.","Pharmacokinetics of macrolides. Comparison of plasma, tissue and free concentrations with special reference to roxithromycin. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7782117/),h,19,183120,DB00778,Roxithromycin
,10212755,MIC90,"Dirithromycin was less active than other macrolides tested (azithromycin clarithromycin, erythromycin) against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis with MIC90 values of 16, 32, and 1 microgram/ml, respectively; an activity that was most similar to roxithromycin.","Comparative in vitro evaluation of dirithromycin tested against recent clinical isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae, including effects of medium supplements and test conditions on MIC results. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10212755/),[μg] / [ml],16,184156,DB00778,Roxithromycin
,10212755,MIC90,"Dirithromycin was less active than other macrolides tested (azithromycin clarithromycin, erythromycin) against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis with MIC90 values of 16, 32, and 1 microgram/ml, respectively; an activity that was most similar to roxithromycin.","Comparative in vitro evaluation of dirithromycin tested against recent clinical isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae, including effects of medium supplements and test conditions on MIC results. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10212755/),[μg] / [ml],32,184157,DB00778,Roxithromycin
,10212755,MIC90,"Dirithromycin was less active than other macrolides tested (azithromycin clarithromycin, erythromycin) against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis with MIC90 values of 16, 32, and 1 microgram/ml, respectively; an activity that was most similar to roxithromycin.","Comparative in vitro evaluation of dirithromycin tested against recent clinical isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae, including effects of medium supplements and test conditions on MIC results. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10212755/),[μg] / [ml],1,184158,DB00778,Roxithromycin
,8855675,duration of treatment,The mean duration of treatment was 6.9 +/- 0.5 days.,An open evaluation of the efficacy and safety of the new macrolide roxithromycin in the treatment of lower respiratory tract infections and pneumonia in Nigerian patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8855675/),,6.9,184473,DB00778,Roxithromycin
,9691325,recovery,The recovery of the macrolides from water and plasma was 80-90%.,Determination of macrolides in biological matrices by high-performance liquid chromatography with electrochemical detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9691325/),%,80-90,187192,DB00778,Roxithromycin
,8537262,Peak plasma concentrations,"Peak plasma concentrations were attained between 0.5 and 5 h, and ranged from 2.3 to 6.8 mg/L.",Roxithromycin disposition in patients on continuous ambulatory peritoneal dialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8537262/),[mg] / [l],2.3 to 6.8,189457,DB00778,Roxithromycin
,8537262,elimination half-life,"The mean elimination half-life was 20.6 +/- 8.7 h, compared with 10 to 14 h previously reported in healthy volunteers given a single 300 mg dose.",Roxithromycin disposition in patients on continuous ambulatory peritoneal dialysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8537262/),h,20.6,189458,DB00778,Roxithromycin
,8537262,elimination half-life,"The mean elimination half-life was 20.6 +/- 8.7 h, compared with 10 to 14 h previously reported in healthy volunteers given a single 300 mg dose.",Roxithromycin disposition in patients on continuous ambulatory peritoneal dialysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8537262/),h,10 to 14,189459,DB00778,Roxithromycin
,8537262,Plasma clearance relative to bioavailability (Clp/F),Plasma clearance relative to bioavailability (Clp/F) ranged from 37.3 to 118.3 mL/min.,Roxithromycin disposition in patients on continuous ambulatory peritoneal dialysis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8537262/),[ml] / [min],37.3 to 118.3,189460,DB00778,Roxithromycin
,8537262,net dialysis clearance,"The percentage of the dose recovered in the dialysate and net dialysis clearance were low, ranging from 1.0 to 3.1% and 0.9 to 1.8 mL/min, respectively.",Roxithromycin disposition in patients on continuous ambulatory peritoneal dialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8537262/),[ml] / [min],0.9 to 1.8,189461,DB00778,Roxithromycin
,2305423,half-life,The half-life for roxithromycin was 12.42 +/- 3.94 h compared with 1.53 +/- 0.42 h for erythromycin.,Single oral dose pharmacokinetics of erythromycin and roxithromycin and the effects of chronic dosing. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2305423/),h,12.42,189983,DB00778,Roxithromycin
,2305423,half-life,The half-life for roxithromycin was 12.42 +/- 3.94 h compared with 1.53 +/- 0.42 h for erythromycin.,Single oral dose pharmacokinetics of erythromycin and roxithromycin and the effects of chronic dosing. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2305423/),h,1.53,189984,DB00778,Roxithromycin
,12016904,Tmax,"The Tmax values of formulation A and B obtained were 1.7 +/- 0.9 and 3.7 +/- 1.6 h, the Cmax values were 4.97 +/- 1.17 and 2.04 +/- 1.26 micrograms.",[Comparison of roxithromycin bioavailability of a conventional and a dispersible tablet formulation]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12016904/),h,1.7,194284,DB00778,Roxithromycin
,12016904,Tmax,"The Tmax values of formulation A and B obtained were 1.7 +/- 0.9 and 3.7 +/- 1.6 h, the Cmax values were 4.97 +/- 1.17 and 2.04 +/- 1.26 micrograms.",[Comparison of roxithromycin bioavailability of a conventional and a dispersible tablet formulation]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12016904/),h,3.7,194285,DB00778,Roxithromycin
,12016904,Cmax,"The Tmax values of formulation A and B obtained were 1.7 +/- 0.9 and 3.7 +/- 1.6 h, the Cmax values were 4.97 +/- 1.17 and 2.04 +/- 1.26 micrograms.",[Comparison of roxithromycin bioavailability of a conventional and a dispersible tablet formulation]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12016904/),μg,4.97,194286,DB00778,Roxithromycin
,12016904,Cmax,"The Tmax values of formulation A and B obtained were 1.7 +/- 0.9 and 3.7 +/- 1.6 h, the Cmax values were 4.97 +/- 1.17 and 2.04 +/- 1.26 micrograms.",[Comparison of roxithromycin bioavailability of a conventional and a dispersible tablet formulation]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12016904/),μg,2.04,194287,DB00778,Roxithromycin
,12016904,AUC0-->infinity,"ml-1 and the AUC0-->infinity values were 62.2 +/- 11.9 and 35.0 +/- 16.9 micrograms.h.ml-1, respectively.",[Comparison of roxithromycin bioavailability of a conventional and a dispersible tablet formulation]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12016904/),[h·μg] / [ml],35.0,194288,DB00778,Roxithromycin
,12016904,relative bioavailability,"Surprisingly, the relative bioavailability of formulation B was found to be only 59.8% +/- 32.6% (P < 0.01).",[Comparison of roxithromycin bioavailability of a conventional and a dispersible tablet formulation]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12016904/),%,59.8,194289,DB00778,Roxithromycin
,2778098,elimination plasma half-life,"At day 6, the elimination plasma half-life had an average value (mean +/- SD) of 19.8 +/- 9.7 h (group I), 21.0 +/- 9.4 h (group II) and 20.8 +/- 6.9 h (group III), respectively.","Pharmacokinetics of a new macrolide, roxithromycin, in infants and children. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778098/),h,19.8,203584,DB00778,Roxithromycin
,2778098,elimination plasma half-life,"At day 6, the elimination plasma half-life had an average value (mean +/- SD) of 19.8 +/- 9.7 h (group I), 21.0 +/- 9.4 h (group II) and 20.8 +/- 6.9 h (group III), respectively.","Pharmacokinetics of a new macrolide, roxithromycin, in infants and children. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778098/),h,21.0,203585,DB00778,Roxithromycin
,2778098,elimination plasma half-life,"At day 6, the elimination plasma half-life had an average value (mean +/- SD) of 19.8 +/- 9.7 h (group I), 21.0 +/- 9.4 h (group II) and 20.8 +/- 6.9 h (group III), respectively.","Pharmacokinetics of a new macrolide, roxithromycin, in infants and children. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778098/),h,20.8,203586,DB00778,Roxithromycin
,2778098,maximum concentration of roxithromycin (Cmax),"The maximum concentration of roxithromycin (Cmax) was attained between 1 and 2 hours after dosing with mean values of 10.1 +/- 3.0 mg/l (group I), 8.7 +/- 4.9 mg/l (group II), 8.8 +/- 7.0 mg/l (group III).","Pharmacokinetics of a new macrolide, roxithromycin, in infants and children. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778098/),[mg] / [l],10.1,203587,DB00778,Roxithromycin
,2778098,maximum concentration of roxithromycin (Cmax),"The maximum concentration of roxithromycin (Cmax) was attained between 1 and 2 hours after dosing with mean values of 10.1 +/- 3.0 mg/l (group I), 8.7 +/- 4.9 mg/l (group II), 8.8 +/- 7.0 mg/l (group III).","Pharmacokinetics of a new macrolide, roxithromycin, in infants and children. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778098/),[mg] / [l],8.7,203588,DB00778,Roxithromycin
,2778098,maximum concentration of roxithromycin (Cmax),"The maximum concentration of roxithromycin (Cmax) was attained between 1 and 2 hours after dosing with mean values of 10.1 +/- 3.0 mg/l (group I), 8.7 +/- 4.9 mg/l (group II), 8.8 +/- 7.0 mg/l (group III).","Pharmacokinetics of a new macrolide, roxithromycin, in infants and children. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2778098/),[mg] / [l],8.8,203589,DB00778,Roxithromycin
,2119954,plasma,"The plasma, gingiva, and alveolar bone peak concentrations were 6.12 +/- 1.94 mg/l, 6.55 +/- 2.54 mg/kg, and 5.09 +/- 1.60 mg/kg, respectively.",Roxithromycin penetration into gingiva and alveolar bone of odontoiatric patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2119954/),[mg] / [l],6.12,207817,DB00778,Roxithromycin
,2119954,peak concentrations,"The plasma, gingiva, and alveolar bone peak concentrations were 6.12 +/- 1.94 mg/l, 6.55 +/- 2.54 mg/kg, and 5.09 +/- 1.60 mg/kg, respectively.",Roxithromycin penetration into gingiva and alveolar bone of odontoiatric patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2119954/),[mg] / [kg],6.55,207818,DB00778,Roxithromycin
,2119954,peak concentrations,"The plasma, gingiva, and alveolar bone peak concentrations were 6.12 +/- 1.94 mg/l, 6.55 +/- 2.54 mg/kg, and 5.09 +/- 1.60 mg/kg, respectively.",Roxithromycin penetration into gingiva and alveolar bone of odontoiatric patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2119954/),[mg] / [kg],5.09,207819,DB00778,Roxithromycin
,2119954,area under the concentration-time curve,"The values of the area under the concentration-time curve for plasma, gingiva, and bone were 59.47 mg/l.h, 51.88 mg/kg.h and 46.80 mg/kg.h, respectively; the half-life values were 7.52 h for plasma and 6.36 and 5.20 h for gingiva and bone, respectively.",Roxithromycin penetration into gingiva and alveolar bone of odontoiatric patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2119954/),[mg] / [h·l],59.47,207820,DB00778,Roxithromycin
,2119954,area under the concentration-time curve,"The values of the area under the concentration-time curve for plasma, gingiva, and bone were 59.47 mg/l.h, 51.88 mg/kg.h and 46.80 mg/kg.h, respectively; the half-life values were 7.52 h for plasma and 6.36 and 5.20 h for gingiva and bone, respectively.",Roxithromycin penetration into gingiva and alveolar bone of odontoiatric patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2119954/),[mg] / [h·kg],51.88,207821,DB00778,Roxithromycin
,2119954,area under the concentration-time curve,"The values of the area under the concentration-time curve for plasma, gingiva, and bone were 59.47 mg/l.h, 51.88 mg/kg.h and 46.80 mg/kg.h, respectively; the half-life values were 7.52 h for plasma and 6.36 and 5.20 h for gingiva and bone, respectively.",Roxithromycin penetration into gingiva and alveolar bone of odontoiatric patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2119954/),[mg] / [h·kg],46.80,207822,DB00778,Roxithromycin
,2119954,half-life,"The values of the area under the concentration-time curve for plasma, gingiva, and bone were 59.47 mg/l.h, 51.88 mg/kg.h and 46.80 mg/kg.h, respectively; the half-life values were 7.52 h for plasma and 6.36 and 5.20 h for gingiva and bone, respectively.",Roxithromycin penetration into gingiva and alveolar bone of odontoiatric patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2119954/),h,7.52,207823,DB00778,Roxithromycin
,2119954,half-life,"The values of the area under the concentration-time curve for plasma, gingiva, and bone were 59.47 mg/l.h, 51.88 mg/kg.h and 46.80 mg/kg.h, respectively; the half-life values were 7.52 h for plasma and 6.36 and 5.20 h for gingiva and bone, respectively.",Roxithromycin penetration into gingiva and alveolar bone of odontoiatric patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2119954/),h,6.36,207824,DB00778,Roxithromycin
,2119954,half-life,"The values of the area under the concentration-time curve for plasma, gingiva, and bone were 59.47 mg/l.h, 51.88 mg/kg.h and 46.80 mg/kg.h, respectively; the half-life values were 7.52 h for plasma and 6.36 and 5.20 h for gingiva and bone, respectively.",Roxithromycin penetration into gingiva and alveolar bone of odontoiatric patients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2119954/),h,5.20,207825,DB00778,Roxithromycin
<,22113743,intrinsic clearance,"In vitro metabolic stability studies point to low intrinsic clearance of the tested macrolides in both microsomes (<1 mL/min/g) and hepatocytes (<1 mL/min/g), indicating good stability.",Investigating the barriers to bioavailability of macrolide antibiotics in the rat. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22113743/),[ml] / [g·min],1,208356,DB00778,Roxithromycin
,22113743,oral bioavailability,"The oral bioavailability in rat was low to moderate (14, 36, 36 and 25% for erythromycin, clarithromycin, roxithromycin and telithromycin, respectively).",Investigating the barriers to bioavailability of macrolide antibiotics in the rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22113743/),%,14,208357,DB00778,Roxithromycin
,22113743,oral bioavailability,"The oral bioavailability in rat was low to moderate (14, 36, 36 and 25% for erythromycin, clarithromycin, roxithromycin and telithromycin, respectively).",Investigating the barriers to bioavailability of macrolide antibiotics in the rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22113743/),%,36,208358,DB00778,Roxithromycin
,22113743,oral bioavailability,"The oral bioavailability in rat was low to moderate (14, 36, 36 and 25% for erythromycin, clarithromycin, roxithromycin and telithromycin, respectively).",Investigating the barriers to bioavailability of macrolide antibiotics in the rat. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22113743/),%,25,208359,DB00778,Roxithromycin
,2696762,half-life,Its half-life in the serum of healthy individuals ranges from 9 to 16 hours.,Roxithromycin--a new macrolide derivative. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2696762/),h,9 to 16,209503,DB00778,Roxithromycin
,2696762,Maximum serum concentrations,Maximum serum concentrations at 2 oral doses of 150 mg a day are reached at 3 to 4 days and vary from 5.5 to 11.1 mg/l.,Roxithromycin--a new macrolide derivative. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2696762/),[mg] / [l],5.5 to 11.1,209504,DB00778,Roxithromycin
,2211451,Peak plasma,Peak plasma and skin concentrations of 7.9 +/- 1.2 mg/l and 31.3 +/- 3.7 mg/kg occurred 2.5 and 4 h after last dosing respectively.,The penetration of roxithromycin into human skin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2211451/),[mg] / [l],7.9,216040,DB00778,Roxithromycin
,2211451,skin concentrations,Peak plasma and skin concentrations of 7.9 +/- 1.2 mg/l and 31.3 +/- 3.7 mg/kg occurred 2.5 and 4 h after last dosing respectively.,The penetration of roxithromycin into human skin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2211451/),[mg] / [kg],31.3,216041,DB00778,Roxithromycin
,2211451,plasma,"The plasma and skin half-lives were 7.7 and 6.0 h, and the mean plasma and skin area under the curve values were 64.3 mg/l.h and 155.3 mg/kg.h.",The penetration of roxithromycin into human skin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2211451/),h,7.7,216042,DB00778,Roxithromycin
,2211451,plasma,"The plasma and skin half-lives were 7.7 and 6.0 h, and the mean plasma and skin area under the curve values were 64.3 mg/l.h and 155.3 mg/kg.h.",The penetration of roxithromycin into human skin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2211451/),h,6.0,216043,DB00778,Roxithromycin
,2211451,skin,"The plasma and skin half-lives were 7.7 and 6.0 h, and the mean plasma and skin area under the curve values were 64.3 mg/l.h and 155.3 mg/kg.h.",The penetration of roxithromycin into human skin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2211451/),h,7.7,216044,DB00778,Roxithromycin
,2211451,skin,"The plasma and skin half-lives were 7.7 and 6.0 h, and the mean plasma and skin area under the curve values were 64.3 mg/l.h and 155.3 mg/kg.h.",The penetration of roxithromycin into human skin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2211451/),h,6.0,216045,DB00778,Roxithromycin
,2211451,half-lives,"The plasma and skin half-lives were 7.7 and 6.0 h, and the mean plasma and skin area under the curve values were 64.3 mg/l.h and 155.3 mg/kg.h.",The penetration of roxithromycin into human skin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2211451/),h,6.0,216046,DB00778,Roxithromycin
,2211451,plasma,"The plasma and skin half-lives were 7.7 and 6.0 h, and the mean plasma and skin area under the curve values were 64.3 mg/l.h and 155.3 mg/kg.h.",The penetration of roxithromycin into human skin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2211451/),[mg] / [h·l],64.3,216047,DB00778,Roxithromycin
,2211451,skin,"The plasma and skin half-lives were 7.7 and 6.0 h, and the mean plasma and skin area under the curve values were 64.3 mg/l.h and 155.3 mg/kg.h.",The penetration of roxithromycin into human skin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2211451/),[mg] / [h·l],64.3,216048,DB00778,Roxithromycin
,2211451,area under the curve,"The plasma and skin half-lives were 7.7 and 6.0 h, and the mean plasma and skin area under the curve values were 64.3 mg/l.h and 155.3 mg/kg.h.",The penetration of roxithromycin into human skin. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2211451/),[mg] / [h·kg],155.3,216049,DB00778,Roxithromycin
,2211451,Skin/plasma concentration ratios,"Skin/plasma concentration ratios were 4.9 +/- 0.5, 9.7 +/- 1.2, 7.6 +/- 0.8 and 5.9 +/- 1.1, at 3, 4, 5 and 6 h after last dosing respectively.",The penetration of roxithromycin into human skin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2211451/),,4.9,216050,DB00778,Roxithromycin
,2211451,Skin/plasma concentration ratios,"Skin/plasma concentration ratios were 4.9 +/- 0.5, 9.7 +/- 1.2, 7.6 +/- 0.8 and 5.9 +/- 1.1, at 3, 4, 5 and 6 h after last dosing respectively.",The penetration of roxithromycin into human skin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2211451/),,9.7,216051,DB00778,Roxithromycin
,2211451,Skin/plasma concentration ratios,"Skin/plasma concentration ratios were 4.9 +/- 0.5, 9.7 +/- 1.2, 7.6 +/- 0.8 and 5.9 +/- 1.1, at 3, 4, 5 and 6 h after last dosing respectively.",The penetration of roxithromycin into human skin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2211451/),,7.6,216052,DB00778,Roxithromycin
,2211451,Skin/plasma concentration ratios,"Skin/plasma concentration ratios were 4.9 +/- 0.5, 9.7 +/- 1.2, 7.6 +/- 0.8 and 5.9 +/- 1.1, at 3, 4, 5 and 6 h after last dosing respectively.",The penetration of roxithromycin into human skin. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2211451/),,5.9,216053,DB00778,Roxithromycin
,12753725,Km,"Both Km and Vm values suggested that saturation of P-GP by telithromycin may occur at a lower dose level in humans than with roxithromycin (Km= 9.8 microM, Vm= 0.3 microM and Km= 45 microM, Vm= 1.1 microM, respectively).","Experimental estimation of the role of P-Glycoprotein in the pharmacokinetic behaviour of telithromycin, a novel ketolide, in comparison with roxithromycin and other macrolides using the Caco-2 cell model. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12753725/),μM,9.8,231668,DB00778,Roxithromycin
,12753725,Vm,"Both Km and Vm values suggested that saturation of P-GP by telithromycin may occur at a lower dose level in humans than with roxithromycin (Km= 9.8 microM, Vm= 0.3 microM and Km= 45 microM, Vm= 1.1 microM, respectively).","Experimental estimation of the role of P-Glycoprotein in the pharmacokinetic behaviour of telithromycin, a novel ketolide, in comparison with roxithromycin and other macrolides using the Caco-2 cell model. ",Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12753725/),μM,0.3,231669,DB00778,Roxithromycin
,12753725,Km,"Both Km and Vm values suggested that saturation of P-GP by telithromycin may occur at a lower dose level in humans than with roxithromycin (Km= 9.8 microM, Vm= 0.3 microM and Km= 45 microM, Vm= 1.1 microM, respectively).","Experimental estimation of the role of P-Glycoprotein in the pharmacokinetic behaviour of telithromycin, a novel ketolide, in comparison with roxithromycin and other macrolides using the Caco-2 cell model. ",Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12753725/),μM,45,231670,DB00778,Roxithromycin
,12753725,Vm,"Both Km and Vm values suggested that saturation of P-GP by telithromycin may occur at a lower dose level in humans than with roxithromycin (Km= 9.8 microM, Vm= 0.3 microM and Km= 45 microM, Vm= 1.1 microM, respectively).","Experimental estimation of the role of P-Glycoprotein in the pharmacokinetic behaviour of telithromycin, a novel ketolide, in comparison with roxithromycin and other macrolides using the Caco-2 cell model. ",Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12753725/),μM,1.1,231671,DB00778,Roxithromycin
,1535579,Peak serum levels,Peak serum levels as measured by HPLC were 6.7 +/- 2.6 (150 mg) and 11.0 +/- 2.2 micrograms/ml (300 mg) and did not differ significantly from the values obtained by MA.,Macrolide pharmacokinetics and dose scheduling of roxithromycin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1535579/),[μg] / [ml],6.7,233511,DB00778,Roxithromycin
,1535579,Peak serum levels,Peak serum levels as measured by HPLC were 6.7 +/- 2.6 (150 mg) and 11.0 +/- 2.2 micrograms/ml (300 mg) and did not differ significantly from the values obtained by MA.,Macrolide pharmacokinetics and dose scheduling of roxithromycin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1535579/),[μg] / [ml],11.0,233512,DB00778,Roxithromycin
,1535579,peak serum levels,"HPLC analysis of a comparable macrolide, clarithromycin, showed peak serum levels of 1.2 +/- 0.6 and 2.3 +/- 0.6 micrograms/ml after oral dosing with 250 and 500 mg in the same subjects.",Macrolide pharmacokinetics and dose scheduling of roxithromycin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1535579/),[μg] / [ml],1.2,233513,DB00778,Roxithromycin
,1535579,peak serum levels,"HPLC analysis of a comparable macrolide, clarithromycin, showed peak serum levels of 1.2 +/- 0.6 and 2.3 +/- 0.6 micrograms/ml after oral dosing with 250 and 500 mg in the same subjects.",Macrolide pharmacokinetics and dose scheduling of roxithromycin. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1535579/),[μg] / [ml],2.3,233514,DB00778,Roxithromycin
,17574935,gradient elution at flow rate,"The analysis was carried out on an ACQUITY UPLC BEH C(18) column (50 mm x 2.1 mm, i.d., 1.7 microm) with gradient elution at flow rate of 0.35 mL/min.",Quantitative determination of azithromycin in human plasma by ultra performance liquid chromatography-electrospray ionization mass spectrometry and its application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17574935/),[ml] / [min],0.35,242687,DB00778,Roxithromycin
,3360966,plasma half-life,The plasma half-life is approximately 12 hours.,Pharmacokinetics of roxithromycin (RU 965). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3360966/),h,12,243092,DB00778,Roxithromycin
less,12482478,analysis time,The analysis time was less than 8 min.,"Quantification of clarithromycin, its 14-hydroxy and decladinose metabolites in rat plasma, gastric juice and gastric tissue using high-performance liquid chromatography with electrochemical detection. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12482478/),min,8,252144,DB00778,Roxithromycin
,2334149,terminal elimination half-life,The terminal elimination half-life was significantly prolonged in the group with severely impaired renal function (15.5 +/- 4.7 h) compared with that of the group with normal renal function (7.9 +/- 2.5 h).,Disposition of roxithromycin in patients with normal and severely impaired renal function. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2334149/),h,15.5,252465,DB00778,Roxithromycin
,2334149,terminal elimination half-life,The terminal elimination half-life was significantly prolonged in the group with severely impaired renal function (15.5 +/- 4.7 h) compared with that of the group with normal renal function (7.9 +/- 2.5 h).,Disposition of roxithromycin in patients with normal and severely impaired renal function. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2334149/),h,7.9,252466,DB00778,Roxithromycin
,2334149,Apparent total body clearance,Apparent total body clearance was significantly reduced in the renally impaired (25.3 +/- 10.5 ml/min) in relation to the group with normal renal function (48.8 +/- 11.1 ml/min).,Disposition of roxithromycin in patients with normal and severely impaired renal function. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2334149/),[ml] / [min],25.3,252467,DB00778,Roxithromycin
,2334149,Apparent total body clearance,Apparent total body clearance was significantly reduced in the renally impaired (25.3 +/- 10.5 ml/min) in relation to the group with normal renal function (48.8 +/- 11.1 ml/min).,Disposition of roxithromycin in patients with normal and severely impaired renal function. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2334149/),[ml] / [min],48.8,252468,DB00778,Roxithromycin
,21073024,retention times,"The internal standard (roxithromycin) was separated from azithromycin on a Hypersil Gold C18 column, with retention times of 10.71 and 13.67 minutes, respectively.",An alternative liquid chromatography-mass spectrometric method for the determination of azithromycin in human plasma and its application to pharmacokinetic study of patients with malaria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21073024/),min,10.71,254710,DB00778,Roxithromycin
,21073024,retention times,"The internal standard (roxithromycin) was separated from azithromycin on a Hypersil Gold C18 column, with retention times of 10.71 and 13.67 minutes, respectively.",An alternative liquid chromatography-mass spectrometric method for the determination of azithromycin in human plasma and its application to pharmacokinetic study of patients with malaria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21073024/),min,13.67,254711,DB00778,Roxithromycin
,21073024,flow rate,"The mobile phase consisted of a mixture of 20 mM ammonium acetate buffer (pH 5.2), acetonitrile and methanol (50:40:10, v/ v/v), running through the column at a flow rate of 0.3 ml/minute.",An alternative liquid chromatography-mass spectrometric method for the determination of azithromycin in human plasma and its application to pharmacokinetic study of patients with malaria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21073024/),[ml] / [min],0.3,254712,DB00778,Roxithromycin
greater,21073024,recoveries,The mean recoveries for azithromycin and the internal standard were greater than 85%.,An alternative liquid chromatography-mass spectrometric method for the determination of azithromycin in human plasma and its application to pharmacokinetic study of patients with malaria. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21073024/),%,85,254713,DB00778,Roxithromycin
